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During the maturation of transfer RNA (tRNA), a variety of chemical modiﬁcations can be introduced at
speciﬁc nucleotide positions post-transcriptionally. 5-Methyluridine (m5U) is one of the most common
and conserved modiﬁcations from eubacteria to eukaryotes. Although TrmA protein in Escherichia coli
and Trm2p protein in Saccharomyces cerevisiae, which are responsible for the 5-methylation of uracil at
position 54 (m5U54) on tRNA, are well characterized, the biological function of the U54 methylation
responsible enzyme in mammalian species remains largely unexplored. Here, we show that the
mammalian tRNA methyltransferase 2 homolog A (TRMT2A) protein harbors an RNA recognition motif in
the N-terminus and the conserved uracil-C5-methyltransferase domain of the TrmA family in the C-
terminus. TRMT2A predominantly localizes to the nucleus in HeLa cells. TRMT2A-overexpressing cells
display decreased cell proliferation and altered DNA content, while TRMT2A-deﬁcient cells exhibit
increased growth. Thus, our results reveal the inhibitory role of TRMT2A on cell proliferation and cell
cycle control, providing evidence that TRMT2A is a candidate cell cycle regulator in mammals.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Transfer RNA (tRNA) is the key adaptor molecule responsible for
the delivery of amino acids to the ribosome, where tRNA partici-
pates in the decoding of mRNA template into protein. Eukaryotic
cytoplasmic tRNA is transcribed by RNA polymerase III as a pre-
cursor molecule in the nucleus. Functional maturation of pre-tRNA
involves a series of processing events, including numerous post-
transcriptional modiﬁcations. To date, more than 100 chemically
distinct post-transcriptional modiﬁcations have been reported forry Animal Resource Center,
ry Animal Resource Center,
no), satoruta@md.tsukuba.ac.
r Inc. This is an open access articltRNAs [1]. These modiﬁcations play essential roles in the ﬁdelity of
translation, the folding and stability of tRNA [2e4] and the recog-
nition of tRNA by the translation machinery [5].
One of the most abundant modiﬁcations found in tRNA is 5-
methyluridine (m5U or rT, ribothymidine). The ubiquitous pres-
ence of m5U at position 54 in the TjC stem-loop of eubacteria and
in eukaryotic elongator tRNAs implies the pivotal role for this
modiﬁcation. In Escherichia coli, the enzyme that catalyzes the
formation of m5U54 is TrmA [6], while in Saccharomyces cerevisiae,
the enzyme responsible for this modiﬁcation is Trm2p [7]. Both
TrmA and Trm2p belong to the S-adenosyl-methionine (SAM)-
dependent methyltransferase family, catalyzing methyl group
transfer from SAM to the C5 of U54 of tRNA [7e9]. Previous studies
have shown that the presence of m5U54 increases the ﬁdelity and
efﬁciency of protein synthesis by stabilizing the three-dimensional
structure of tRNA in vitro [10,11]. In mammals, TRMT2A and
TRMT2B are considered to be homologs of yeast Trm2p [12]. Thee under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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identity (36%) with that of Trm2p. Similar to Trm2p, TRMT2A har-
bors a putative RNA recognition motif (RRM) in the N-terminus. By
contrast, the shared identity between TRMT2B and Trm2p is low
(28%), and the TRMT2B protein does not have an identiﬁable RRM
motif. This evidence indicates that TRMT2A is the likely mamma-
lian homolog of Trm2p, for which the biological function remains
largely unexplored.
Here, we investigated the effects of TRMT2A on the growth in
mammalian culture systems. TRMT2A-overexpressing HeLa cells
exhibit decreased cell growth and altered cell cycle proﬁle, while
Trmt2a knock-out (KO) mouse embryonic ﬁbroblasts (MEFs) show
elevated cell growth. Our results provide evidence that TRMT2A
exerts an inhibitory effect on cell proliferation and is a promising
cell cycle regulator in mammals.
2. Materials and methods
2.1. Plasmids
The coding region of human TRMT2A was PCR-ampliﬁed from
cDNA extracted from HeLa cells using the primers F 50-
CTGAATTCGATGAGTGAGAACCTCGACAAC-30 and R 50-
CGGGATCCCTAGGATGAGGGGAAGGTCCCAG-3’. EcoRI and BamHI
restriction sites were added to the primers to facilitate directional
cloning into the pEGFP-c1 (BD Biosciences) vector for expression as
an EGFP-tagged fusion protein. Sequences were veriﬁed by Sanger
sequencing using a BigDye™ Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems) and were analyzed on a 3500 Genetic
Analyzer sequencing machine (Applied Biosystems). Expression of
GFP-TRMT2A in HeLa cells was conﬁrmed by immunoblotting and
immunoﬂuorescence assay.
2.2. Transfection and generation of stable cell lines
HeLa cells and derived cell lines were grown in Dulbecco's
modiﬁed Eagle's medium (DMEM) (Gibco) supplemented with 8%
fetal bovine serum (Sigma). To establish HeLa cells stably express-
ing GFP (GFP-HeLa) and GFP-TRMT2A (GFP-TRMT2A-HeLa), the
cells were transfected with the indicated expression plasmids with
Lipofectamine 2000 (Invitrogen) in Opti-MEM (Gibco) according to
the manufacture's instructions and selected with G418 (Gibco) at a
concentration of 1mg/ml for 1 month. Positive clones with more
than 95% GFP (clone 1) and GFP-TRMT2A (clone 1) expression
veriﬁed by immunoﬂuorescence assay and ﬂow cytometry analysis
were selected for further experiments.
2.3. Immunoblotting
Proteins from whole cell lysates prepared using NP-40 lysis
buffer (1% NP-40, 50mM Tris (pH 8.0), 150mM NaCl, 0.5% sodium
deoxycholate, 0.1% SDS) with complete protease inhibitor (Roche)
were resolved by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis (10% acrylamide gel) and were transferred to poly-
vinylidene diﬂuoride (PVDF) membrane (Merck Millipore). After
blocking, the primary antibodies used were TRMT2A (Santa Cruz,
sc-86496) and b-actin (MBL, PM053-7). The immunoblots were
developed using LAS-3000 (FujiFilm).
2.4. Immunoﬂuorescence
Slide-cultured cells were harvested at 24 h post-plating. After
air-drying, slides were ﬁxed with 4% paraformaldehyde at room
temperature for 20min and washed with PBS for 5min. Cells were
permeabilized with 0.1% Triton X-100 for 5min and subjected toDNA staining with Hoechst 33342 (Molecular Probes) in Flur-
omount medium (COSMO BIO). Slides were observed by Biorevo
BZ-9000 ﬂuorescence microscopy (Keyence), and images were ac-
quired using BZ-II Analyzer software (Keyence).2.5. Cell proliferation and survival
Cells were seeded in 24-well plates (2 104 per well) in tripli-
cate. At 24, 48, 72, and 96 h post-plating, cells were trypsinized and
stained with trypan blue. Live cells with positive trypan blue
staining were counted using a hemocytometer. The cell survival
rate was conﬁrmed using a TC10 automated cell counter (Bio-Rad).2.6. Clonogenic assay
Cells were seeded in 6-well plates (100 cells per well) and
cultured for 14 days. Colonies formed were ﬁxed with 100% cold
methanol for 30min and then stained with 0.5% crystal violet (in
20% methanol) for 1 h. After air-drying, colony numbers were
counted. Plate efﬁciency (PE) reﬂected the ratio of the number of
colonies to the number of cells originally seeded.2.7. Cell cycle analysis
Cells were seeded in 6-cm plates at 4 105 cells per dish. At 24 h
after cell seeding, culture media were harvested to collect mitotic
cells, which had rounded and were easily ﬂoating. Attached cells
were trypsinized and resuspended in 1ml of complete DMEM
culture medium. DNA was stained with 5 mM Vybrant DyeCycle
Violet (Invitrogen) at 37 C for 30min. Cell cycle distribution ac-
cording to DNA contents was determined by CytoFLEX (Beckman
Coulter) and analyzed using CytoExpert software (Beckman
Coulter).2.8. Preparation of mouse embryonic ﬁbroblasts (MEFs)
Primary mouse embryonic ﬁbroblasts (MEFs) were prepared
from 13.5-day-old (E13.5) embryos derived fromWT or Trmt2a KO
C57BL/6J mice. Isolated embryos were dissected to remove the
heads and internal organs. Tails were cut to isolate DNA for geno-
typing. Embryo trunks were minced and digested with 0.25%
trypsin at 37 C for 30min. Cells were dispersed and applied to a
70-mm cell strainer (BD Biosciences). After centrifugation, cells
were resuspended in MEF medium (DMEM with 10% FBS, 200mM
L-Glutamine (Gibco), 100 U/mL penicillin/streptomycin (Gibco),
1mM sodium pyruvate (Gibco), 0.1mM MEM non-essential amino
acids (Gibco) and 0.1M 2-mercaptoethanol (Wako)) and were
plated in a 10-cm dish precoated with 0.1% gelatin (Sigma).2.9. Total RNA extraction, cDNA synthesis and quantitative real-
time PCR
Total RNA from MEFs was extracted with an RNA isolation kit
(MACHEREY-NAGEL) and reverse transcribed to cDNA using a
QuantiTect Reverse Transcription kit (Qiagen). Real-time PCR was
performed using SYBRGreen PCRmaster mix (TAKARA) in a Thermal
Cycler Dice Real Time system (TAKARA). Experiments were con-
ducted in duplicate, with two independent experiments performed.
The primers used for TRMT2A detection were F 50-
GGCTCCGAAGGTGAAGAGAG-30 and R 50-CCTGCCA-
CAGTGGAACTCAA-3’. The primers used for HPRT, which served as a
normalization control, were F 50-TTGTTGTTGGATATGCCCTTGACTA-
30 and R 50-AGGCAGATGGCCACAGGACTA-3’.
Fig. 1. Predicted domains and sequence alignment of TRMT2A and its homologs.
(A) Annotated phylogenetic tree and predicted domains of human TRMT2A and its
homologs from E. coli, S. cerevisiae and mouse. (B) Amino acid sequence alignment of
TRMT2A and its homologs. The conserved motifs of the SAM binding site within the
methyltransferase domain are noted over the sequence alignment. The gene tree and
sequence alignment were predicted and constructed using the online program Clustal
Omega.
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All data are presented as the means± SEM. P-values were
calculated using a two-tailed Welch's t-test. P-values less than 0.05
were considered to be statistically signiﬁcant.
3. Results
3.1. TRMT2A is conserved with TrmA protein
The humanTRMT2A gene is located on chromosome 22q11.2 and
is predicted to encode a 625-amino-acid protein with unidentiﬁed
function. Amino acid sequence prediction based on NCBI conserved
domain search [13] revealed that TRMT2A is a homolog of TrmA of
E. coli and Trm2p of S. cerevisiae, containing an N-terminal RNA
recognition motif (RRM) responsible for RNA binding and a C-ter-
minal class I S-adenosyl methionine (SAM) methyltransferase
domain conserved across the TrmA family (Fig. 1A). When aligned
with TrmA and Trm2p, both human and mouse TRMT2A show the
conserved SAM binding motifs and a strong homology between the
C-terminal ends (Fig. 1B). The identity between human and mouse
TRMT2A protein is 81%, implying the conserved function in mam-
mals. In addition, sequence analysis using NLStradamus [14]
revealed a nuclear localization signal (NLS) located after the RRM in
Trm2p and in mouse and human TRMT2A proteins, suggesting the
nuclear localization of the eukaryotic homologs (Fig. 1A).
3.2. TRMT2A mainly localizes to the nucleus
To analyze the biological function of TRMT2A, an expression
construct of N-terminal GFP-tagged TRMT2A was generated. The
construct was transfected into HeLa cells, and GFP-TRMT2A-HeLa
cells were generated to elucidate the effects of increased TRMT2A
expression on cell properties. GFP-HeLa cells stably expressing GFP
vector were also established as a control. The expression of GFP and
GFP-TRMT2A was conﬁrmed by immunoblotting using TRMT2A
antibody (Fig. 2A) and immunoﬂuorescence (Fig. 2B).
In S. cerevisiae, tRNA U54 methylation was reported to be an
early event in tRNA processing because unspliced pre-tRNA has
been shown to carry the m5U nucleoside [15,16]. In vertebrates, the
intron-containing pre-tRNA is restricted to the nucleus [17],
implying that TRMT2A resides and catalyzes the m5U modiﬁcation
in the nucleus. The subcellular localization of TRMT2A in HeLa
stable cells was conﬁrmed by immunoﬂuorescence assay (Fig. 2B).
TRMT2A exhibited a homogeneous pattern in the nucleus by
immunoﬂuorescence microscopy, while the GFP control alone
showed a diffuse cytosolic and nuclear localization. Accordingly,
the existence of a putative NLS and the observed localization of
TRMT2A indicate a role in pre-tRNA methylation in the nucleus.
3.3. TRMT2A exerts an inhibitory effect on cell growth
A previous study revealed that the transcriptional kinetics of
mouse TRMT2A gene oscillate during the progression of the cell
cycle, peaking in S-phase and decreasing during mitosis [18]. This is
a typical expression pattern for many known cell cycle regulators,
such asMCM and Cdk1, implying that TRMT2Amight be a novel cell
cycle-regulating protein. To examine whether TRMT2A inﬂuences
cell growth, cell proliferation was monitored in GFP-TRMT2A-HeLa
cells. Ectopic expression of TRMT2A signiﬁcantly retarded cellular
proliferation (Fig. 3A). The decrease in cell number was not due to
the increase in cell death because viability was conﬁrmed to be
Fig. 2. Subcellular localization of TRMT2A. (A) GFP-HeLa and GFP-TRMT2A-HeLa
were seeded and harvested at 24 h post-plating. The protein expression levels were
resolved by 10% SDS-PAGE. b-actin served as a loading control. (B) Individual cell
expression of GFP and GFP-TRMT2A in stable cell lines was conﬁrmed by immuno-
ﬂuorescence. DNA was stained with Hoechst 33342.
Fig. 3. TRMT2A overexpression in HeLa cells results in reduced cell proliferation
and an altered cell cycle proﬁle. (A) (B) GFP-HeLa and GFP-TRMT2A-HeLa cells were
seeded into 24-well plates in triplicate, and cell numbers were counted at 24, 48, 72,
and 96 h in culture. One representative result is shown from three independent ex-
periments. Cell viability was examined by using the trypan blue exclusion method. (C)
(D) GFP-HeLa and GFP-TRMT2A-HeLa cells were seeded into 6-well plates in triplicate.
After 14 days of culture, the number of colonies formed was counted, and the size of
randomly selected colonies (n > 30) from each cell was measured by using BZ-II
Analyzer software. One representative result is shown from four independent exper-
iments. (E) Asynchronous GFP-HeLa and GFP-TRMT2A-HeLa cells were seeded. At 24 h
post-plating, cells were harvested and stained with Vybrant DyeCycle Violet. The cell
cycle proﬁles were analyzed using ﬂow cytometry. Percentages of the cell cycle proﬁles
of four independent experiments are shown. *p < 0.05; ****p < 0.001. Differences were
compared with the GFP control.
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verify the inhibitory inﬂuence of TRMT2A on cell growth over a
longer time period and to monitor the growth capacity at the single
cell level, a clonogenic assay was performed. A plating efﬁciency of
approximately 80% was observed in GFP-HeLa control cells, while
only 60% of plated GFP-TRMT2A-HeLa cells formed colonies after 14
days of culturing (Fig. 3C). In addition, colonies of GFP-TRMT2A-
HeLa cells displayed a marked reduction in size (Fig. 3D),
implying that the increased expression of TRMT2A is adverse to cell
proliferation.
3.4. Overexpression of TRMT2A leads to enrichment of the G2/M
phase population
Reduced proliferation might be due to the perturbation of the
cell cycle. To examine whether overexpression of TRMT2A in HeLa
cells causes alterations in the cell cycle, the cellular DNA content
was quantiﬁed by ﬂow cytometry (Fig. 3E). The results showed that
the G1 population decreased while the G2/M population increased
in GFP-TRMT2A-HeLa cells, indicating the slower mitosis upon
ectopic expression of TRMT2A.
3.5. Trmt2a KO MEFs exhibit increased cell proliferation
To conﬁrm the inﬂuence of TRMT2A on cell proliferation, mouse
embryonic ﬁbroblasts (MEFs) were generated from Trmt2a knock-
out (KO) mice established in our laboratory. The KO of Trmt2a
was conﬁrmed at the transcript (Fig. 4A) and protein (Fig. 4B) levels
by RT-qPCR and immunoblotting, respectively. Contrary to the ef-
fects of overexpression observed in GFP-TRMT2A-HeLa cells,
Trmt2a KO MEFs exhibited signiﬁcantly increased cell growth
compared with the WT control (Fig. 4C). Taken together, these re-
sults suggest that TRMT2A negatively regulates cell proliferation in
mammalian cells.
4. Discussion
Post-transcriptional modiﬁcations of tRNA occur across all
kingdoms of life. These modiﬁcations have been shown to play
essential roles in the structural stability of tRNA and the functional
regulation of translation. The 5-methyluridine is one of the most
common and conserved modiﬁed nucleosides from most eubac-
teria to eukaryotes in the majority of tRNA species. Despite inten-
sive efforts to understand the roles of m5U and the corresponding
methyltransferases in E. coli and S. cerevisiae, it is still difﬁcult to
deﬁne the biological functions due to the variation in reported
phenotypes. For example, an E. coli point mutant strain completelylacking m5U54 only showed a mild reduction in growth, while
strains with disrupting insertions in relatively early trmA genes are
not viable, suggesting that the TrmA protein possesses other crucial
functions in addition to methyltransferase activity [19,20]. In
S. cerevisiae, mutation or deletion strains of Trm2 are viable and
exhibit no obvious phenotype [7,21]. This is not to say that the
physiological role and functional signiﬁcance of this methylation
and the responsible enzymes in mammals have remained
Fig. 4. Trmt2a KO MEFs exhibit increased cell proliferation. Trmt2a KO mouse embryonic ﬁbroblasts (MEFs) were derived from KO mice. The knock-out efﬁciency was conﬁrmed
at the (A) transcript and (B) protein levels. (C) WT and Trmt2a KO MEFs were seeded into 24-well plates in triplicate, and cell numbers were counted at 24, 48, 72, and 96 h in
culture. One representative result is shown from two independent experiments. **p < 0.01; ***p < 0.005. Differences were compared with the WT control.
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of the TrmA family and is a promising cell cycle-regulating protein.
Overexpression of TRMT2A leads to reduced cell proliferation and
an increase in the G2/M population, implying that increased
TRMT2A expression is disadvantageous to cell growth and cell cycle
progression. The inhibitory effect of TRMT2A on cell proliferation is
conﬁrmed by the observation in which Trmt2a KO MEFs exhibit
faster cell growth than WT cells. Together, these results provide
evidence for the conserved function of mammalian TRMT2A in cell
proliferation. In addition, we demonstrated that TRMT2A genes in
mammals are dispensable for survival since KO cells were viable.
Although the m5U54 is a universal modiﬁcation in E. coli, the
m5U54 contents in eukaryotic tRNA vary. In mammals, including
humans, many tRNAs have been reported to lack the 5-
methyluridine at position 54, showing only approximately 50% of
modiﬁed uridine in total tRNA [22,23]. For example, in the initiator
tRNAiMet, 5-methyluridine is completely replaced by adenosine,
while in tRNAVal from mouse myeloma, unmethylated uridine is
present instead of methylated uridine [24,25]. In some other tRNAs,
including tRNAPhe, partial conversion of uridine to methyluridine
has been revealed [26,27]. We also observed incomplete 5-
methyluridine modiﬁcation because the m5U levels in HeLa cells
are much less methylated than control tRNAs extracted from E. coli
by tRNA hydrophilic interaction liquid chromatography (HILIC)
analysis (methods modiﬁed from Ref. [28], data not shown). It is
interesting that partially methylated uridine in tRNAs puriﬁed from
human placenta and rat liver can be fully modiﬁed in vitro by an
excess amount of TrmA of E. coli [29]. Hence, we hypothesized that
overexpression of TRMT2A in HeLa cells might lead to increased
levels of 5-methyluridine. However, the m5U levels in the entire
pool of tRNAs extracted from GFP-TRMT2A-HeLa cells were meth-
ylated and comparable with those of GFP control cells, as demon-
strated by tRNA HILIC analysis (data not shown), implying that
increased amounts of TRMT2A do not affect the homeostasis of
m5Umodiﬁcation in HeLa cells. On the other hand, our unpublished
results demonstrated that 5-methyluridine levels in tRNAs extrac-
ted from Trmt2a KO mice were completely lost. Hence, further
experiments to elucidate the speciﬁc tRNA targets of TRMT2A in
mammalian cells will be required to understand the signiﬁcance of
5-methyluridine and TRMT2A.
In the past few decades, observation of the elevated levels of
tRNA methyltransferases in cancer cells led to the hypothesis that
overmethylation of tRNA is associated with carcinogenesis [30].
However, the roles and mechanisms behind these connections
remain to be explored. A study analyzing tRNA base composition
fromMorris hepatomas and rat liver revealed less 5-methyluridinein hepatomas than in normal liver tissue. However, the comparison
of tRNAs from two tumors could not provide evidence for a distinct
correlation between degrees of tRNAmodiﬁcation and growth rates
and the histological characteristics of the tumors [31]. Another
study proﬁling modiﬁed nucleosides showed elevated m5U54
levels in the cell culture supernatants in MCF-7 breast cancer cells
compared with nontumorigenic MCF-10A mammary epithelial
cells [32]. One of the reasons for the differences observed between
these experiments may result from the origins of cancer and the
cellular compartments where tRNA was extracted. Recent clinical
screenings have suggested overexpression of TRMT2A as a novel
biomarker in HER2þ breast cancer patients, with a higher risk of
recurrence [33]. Of note, the TRMT2A expression pattern reported is
a cytoplasmic form. Since the U54 methylation was reported to
occur in the nucleus, and we observed a uniform nuclear localiza-
tion of GFP-tagged TRMT2A, it is possible that cytoplasmic
expression of TRMT2A is an aberrant form and perturbs the HER2
signaling pathway independent of its methyltransferase activity.
Taken together, systematic analysis and comprehensive map-
ping of individual tRNA species and proteins altered by aberrant
m5U54 and TRMT2A are required. Understanding the role of
TRMT2A-catalyzed m5U54 will uncover the target proteins and the
underlying signaling pathways of TRMT2A in both physiological
and pathological conditions.
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